Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254612 | 1.00 | GPR52 (0.50) | GPR52HCAR2 | |
| SCHEMBL5256854 | 0.88 | HDAC3 (0.42) | GPR52HCAR2 | |
| SCHEMBL141902 | 0.88 | HDAC3 (0.42) | GPR52HCAR2 | |
| SCHEMBL9715286 | 0.79 | GPR52 (0.57) | GPR52 | |
| SCHEMBL7762164 | 0.79 | GPR52 (0.57) | GPR52 | |
| SCHEMBL7762166 | 0.79 | GPR52 (0.57) | GPR52 | |
| SCHEMBL10539956 | 0.79 | GPR52 (0.46) | GPR52 | |
| SCHEMBL10539962 | 0.79 | GPR52 (0.46) | GPR52 | |
| SCHEMBL261253 | 0.78 | MAOB (0.61) | HCAR2 | |
| SCHEMBL145088 | 0.78 | MAOB (0.61) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411004-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | National University of Singapore (SG) | 2012-02-01 | — | — | EP | claimed |
| US-20120015923-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-01-19 | — | — | US | claimed |
| WO-2010110748-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2010-09-30 | — | — | WO | claimed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-116615468-A | Polymer particles | 昆士兰科技大学 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225811-A1 | POLYMER PARTICLES | Queensland University Of Technology (AU) | 2023-08-16 | — | — | EP | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
| US-4514401-A | CARDIOTONICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015923-A1 | USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS | NFKBIA, CCL11, IL5 | GPR52 1748/4885HCAR2 1739/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | GPR52 3882/4885HCAR2 2386/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | GPR52 3358/4885HCAR2 3405/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | GPR52 3882/4885HCAR2 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.